Results 171 to 180 of about 1,678,519 (353)

CTLA-4: a negative regulator of autoimmune disease. [PDF]

open access: yes, 1996
CTLA-4, a CD28 homologue expressed on activated T cells, binds with high affinity to the CD28 ligands, B7-1 (CD80) and B7-2 (CD86). This study was designed to examine the role of CTLA-4 in regulating autoimmune disease.
Bluestone, JA   +4 more
core  

Remission-induction regimens in acute nonlymphocytic leukemia.

open access: yesThe Western journal of medicine, 1982
A sequential study was carried out involving 40 adults with acute nonlymphocytic leukemia (ANLL). The first 20 patients were treated with cytarabine (Ara-C) and 6-thioguanine (6-TG), the second 20 with a regimen that added a three-day course of daunomycin (DNM) to the Ara-C and 6-TG therapy.
D C, Brennan, J P, Lewis
openaire   +1 more source

Cancer‐Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities

open access: yesAdvanced Science, EarlyView.
ABSTRACT Cancer‐associated fibroblasts (CAFs) are the predominant stromal components within the tumor microenvironment (TME), playing multifaceted roles in cancer progression through dynamic interactions with neoplastic and immune cells. Emerging evidence has revealed remarkable heterogeneity and plasticity of CAFs, which originate from diverse ...
Rujiao Liu   +4 more
wiley   +1 more source

Redefining Dendritic Cell Vaccines: Synergistically Co‐priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines

open access: yesAdvanced Science, EarlyView.
Dendritic cells (DC) vaccine is an important type of vaccines. However, the limited efficacy of DC vaccines hinders their widely application. This study redefines DC vaccines and provides a new DC‐BC vaccine that have much better therapeutic efficacy.
Xiangxiang Xu   +11 more
wiley   +1 more source

PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations. [PDF]

open access: yesClin Kidney J, 2023
Casal Moura M   +6 more
europepmc   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang   +10 more
wiley   +1 more source

Mesoscale Recovery of Microglial and Neuronal Dynamics After Craniotomy Across Wide Cortex in Transgenic Mice

open access: yesAdvanced Science, EarlyView.
This study employs longitudinal fluorescence imaging in transgenic mice to map post‐craniotomy cortical recovery. We identify distinct neuroimmune recovery phases: microglial structural inflammation peaks at ∼10 days, neuronal structural intensity peaks at ∼14 days and correlates with microglial activity, and functional network modularity is most ...
Guihua Xiao   +13 more
wiley   +1 more source

PM10 Impairs CD56dim NK Cell Cytotoxicity via FNBP1 Suppression to Exacerbate Rheumatoid Arthritis: Insights from Multimodal Multi‐Omics

open access: yesAdvanced Science, EarlyView.
This study, through multi‐omics approaches and animal models, revealed that air pollutant PM10 exacerbates the progression of rheumatoid arthritis (RA) by suppressing FNBP1 expression and impairing the cytotoxic function of CD56dim NK cells. The “PM10–FNBP1–NK cells” axis provided novel insights into the environmental pathogenesis of RA and suggested ...
Runhan Zhao   +11 more
wiley   +1 more source

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. [PDF]

open access: yesBMC Cancer, 2022
Wendler J   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy